Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A0CY
|
|||
| Former ID |
DNCL002115
|
|||
| Drug Name |
CNDO-109
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2], [3] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [3] | ||
| Company |
Coronado Biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01520558) CNDO-109-AANK for AML in First Complete Remission (CR1). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.